Top

Published in:

Open Access 01-12-2014 | Research

Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer

Authors: Wenshuai Pang, Xin Tian, Fan Bai, Ruiyu Han, Juan Wang, Haitao Shen, Xianghong Zhang, Yueping Liu, Xia Yan, Feng Jiang, Lingxiao Xing

Published in: Molecular Cancer | Issue 1/2014

Abstract

Background

Pim-1 kinase is a proto-oncogene and its dysregulation contributes to tumorigenesis and progression of a variety of malignancies. Pim-1 was suggested as a therapeutic target of cancers. The functional relevance of Pim-1 and the mechanism underlying its dysregulation in lung tumorigenesis remained unclear. This study aimed to investigate if Pim-1 has important functions in non-small-cell lung cancer (NSCLC) by: 1) evaluating the clinicopathologic significance of Pim-1 through analysing its expression in 101 human NSCLCs tissues using quantitative PCR, Western Blot and immunohistochemical studies, 2) determining its role in NSCLC and drug resistance using in vitro assays, and 3) investigating the regulatory mechanism of Pim-1 dysregulation in lung tumorigenesis.

Results

Pim-1 was upregulated in 66.2% of the lung tumor tissues and its expression was significantly related to advanced stage (P = 0.019) and lymph node metastasis (P = 0.026). Reduced Pim-1 expression suppressed NSCLC cell growth, cell cycle progression and migration in vitro. Pim-1 was a novel target of miR-486-5p determined by luciferase report assay, and ectopic miR-486-5p expression in cancer cells reduced Pim-1 expression. Furthermore, eukaryotic translation initiation factor 4E (eIF4E) controlled the synthesis of Pim-1 in NSCLC cells, and its expression was positively associated with that of Pim-1 in NSCLC tissue specimens (r = 0.504, p < 0.001). The downregulated miR-486-5p and upregulated eIF4E in NSCLC cells led to the overexpression of Pim-1 by relieving the inhibitory effect of the 3′-UTR or 5′-UTR of Pim-1 mRNA, respectively. Moreover, Pim-1 knockdown sensitized NSCLC cells to cisplatin and EGFR tyrosine kinase inhibitor, gefitinib.

Conclusions

Pim-1 kinase could be a critical survival signaling factor in NSCLC, and regulated by miR-486-5p and eIF4E. Pim-1 kinase may provide a potential target for diagnosis and treatment for lung cancer.

Available only for authorised users

Breuer M, Wientjens E, Verbeek S, Slebos R, Berns A: Carcinogen-induced lymphomagenesis in pim-1 transgenic mice: dose dependence and involvement of myc and ras. Cancer Res. 1991, 51: 958-963.PubMed

Van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, Berns A: Predisposition to lymphomagenesis in pim-1 transgenicmice: cooperation with c-myc and N-myc in murine leukemia virus–induced tumors. Cell. 1989, 56: 673-682. 10.1016/0092-8674(89)90589-8CrossRefPubMed

Nawijn MC, Alendar A, Berns A: For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011, 11: 23-34. 10.1038/nrc2986CrossRefPubMed

Amson R, Sigaux F, Przedborski S, Flandrin G, Givol D, Telerman A: The human protooncogene product p33pim is expressed during fetalhematopoiesisand in diverse leukemias. Proc Natl Acad Sci U S A. 1989, 86: 8857-8861. 10.1073/pnas.86.22.8857PubMedCentralCrossRefPubMed

Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM: Delineation of prognostic biomarkers in prostate cancer. Nature. 2001, 412: 822-826. 10.1038/35090585CrossRefPubMed

Peltola K, Hollmen M, Maula SM, Rainio E, Ristamäki R, Luukkaa M, Sandholm J, Sundvall M, Elenius K, Koskinen PJ, Grenman R, Jalkanen S: pim-1 Kinase expression predicts radiation response in squamocellularcarcinoma of head and neck and is under the control of epidermal growth factor receptor. Neoplasia. 2009, 11: 629-636.PubMedCentralCrossRefPubMed

Weirauch U, Beckmann N, Thomas M, Grünweller A, Huber K, Bracher F, Hartmann RK, Aigner A: Functional role and therapeutic potential of the Pim-1 kinase in colon carcinoma. Neoplasia. 2013, 15: 783-794.PubMedCentralCrossRefPubMed

Xu D, Allsop SA, Witherspoon SM, Snider JL, Yeh JJ, Fiordalisi JJ, White CD, Williams D, Cox AD, Baines AT: The oncogenic kinase Pim-1 is modulated by K-Rassignaling and mediates transformed growth and radioresistance in human pancreatic ductal adenocarcinoma cells. Carcinogenesis. 2011, 32: 488-495. 10.1093/carcin/bgr007PubMedCentralCrossRefPubMed

Zemskova M, Sahakian E, Bashkirova S, Lilly M: The pIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem. 2008, 283: 20635-20644. 10.1074/jbc.M709479200PubMedCentralCrossRefPubMed

10.

Hu XF, Li J, Vandervalk S, Wang Z, Magnuson NS, Xing PX: PIM-1–specific mAb suppresses human and mouse tumor growth by decreasing PIM-1 levels, reducing Akt phosphorylation, and activating apoptosis. J Clin Invest. 2009, 119: 362-375.PubMedCentralPubMed

11.

Cen B, Mahajan S, Wang W, Kraft AS: Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res. 2013, 73: 3402-3411. 10.1158/0008-5472.CAN-12-4619PubMedCentralCrossRefPubMed

12.

Siu A, Virtanen C, Jongstra J: PIM kinase isoform specific regulation of MIG6 expression and EGFR signaling in prostate cancer cells. Oncotarget. 2011, 2: 1134-1144.PubMedCentralCrossRefPubMed

13.

Warnecke-Eberz U, Bollschweiler E, Drebber U, Pohl A, Baldus SE, Hoelscher AH, Metzger R: Frequent down-regulation of pim-1 mRNA expression in non-small cell lung cancer is associated with lymph node metastases. Oncol Rep. 2008, 20: 619-624.PubMed

14.

Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K: Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem. 2008, 283: 33394-33405. 10.1074/jbc.M804788200PubMedCentralCrossRefPubMed

15.

Jin Y, Tong DY, Chen JN, Feng ZY, Yang JY, Shao CK, Li JP: Overexpression of osteopontin, avb3 and Pim-1 associated with prognostically important clinicopathologic variables in non-small cell lung cancer. PLoS One. 2012, 7: e48575- 10.1371/journal.pone.0048575PubMedCentralCrossRefPubMed

16.

Bartel DP: MicroRNAs: target recognition and regulatory functions. Cell. 2009, 136: 215-233. 10.1016/j.cell.2009.01.002PubMedCentralCrossRefPubMed

17.

Eiring AM, Harb JG, Neviani P, Garton C, Oaks JJ, Spizzo R, Liu S, Schwind S, Santhanam R, Hickey CJ, Becker H, Chandler JC, Andino R, Cortes J, Hokland P, Huettner CS, Bhatia R, Roy DC, Liebhaber SA, Caligiuri MA, Marcucci G, Garzon R, Croce CM, Calin GA, Perrotti D: miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts. Cell. 2010, 140: 652-665. 10.1016/j.cell.2010.01.007PubMedCentralCrossRefPubMed

18.

Thomas M, Lange-Grünweller K, Weirauch U, Gutsch D, Aigner A, Grünweller A, Hartmann RK: The proto-oncogene Pim-1 is a target of miR-33a. Oncogene. 2012, 31: 918-928. 10.1038/onc.2011.278CrossRefPubMed

19.

Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ: Hypoxiainducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell. 2009, 35: 856-867. 10.1016/j.molcel.2009.09.006PubMedCentralCrossRefPubMed

20.

Yu L, Todd NW, Xing L, Xie Y, Zhang H, Liu Z, Fang H, Zhang J, Katz RL, Jiang F: Early detection of lung adenocarcinoma in sputum by a panel of microRNA markers. Int J Cancer. 2010, 127: 2870-2878. 10.1002/ijc.25289PubMedCentralCrossRefPubMed

21.

Xing L, Todd NW, Yu L, Fang H, Jiang F: Early detection of squamous cell lung cancer in sputum by a panel of microRNA markers. Mod Pathol. 2010, 23: 1157-1164. 10.1038/modpathol.2010.111CrossRefPubMed

22.

Shen J, Todd NW, Zhang H, Yu L, Lingxiao X, Mei Y, Guarnera M, Liao J, Chou A, Lu CL, Jiang Z, Fang H, Katz RL, Jiang F: Plasma microRNAs as potential biomarkers for non-small-cell lung cancer. Lab Invest. 2011, 91: 579-587. 10.1038/labinvest.2010.194PubMedCentralCrossRefPubMed

23.

Wang J, Tian X, Han R, Zhang X, Wang X, Shen H, Xue L, Liu Y, Yan X, Shen J, Mannoor K, Deepak J, Donahue JM, Stass SA, Xing L, Jiang F: Downregulation of miR-486-5p contributes to tumor progression and metastasis by targeting protumorigenic ARHGAP5 in lung cancer. Oncogene. 2014, 33: 1181-1189. 10.1038/onc.2013.42PubMedCentralCrossRefPubMed

24.

Graff JR, Zimmer SG: Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mRNAs. Clin Exp Metastasis. 2003, 20: 265-273. 10.1023/A:1022943419011CrossRefPubMed

25.

De Benedetti A, Graff JR: eIF-4E expression and its role in malignancies and metastases. Oncogene. 2004, 23: 3189-3199. 10.1038/sj.onc.1207545CrossRefPubMed

26.

Hoover DS, Wingett DG, Zhang J, Reeves R, Magnuson NS: Pim-1 protein expression is regulated by its 5′-untranslated region and translation initiation factor elF-4E. Cell Growth Differ. 1997, 8: 1371-1380.PubMed

27.

Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, Kronkaitis A, Li J, White A, Mische S, Farmer B: Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem. 2005, 280: 6130-6137. 10.1074/jbc.M409123200CrossRefPubMed

28.

Tan X, Qin W, Zhang L, Hang J, Li B, Zhang C, Wan J, Zhou F, Shao K, Sun Y, Wu J, Zhang X, Qiu B, Li N, Shi S, Feng X, Zhao S, Wang Z, Zhao X, Chen Z, Mitchelson K, Cheng J, Guo Y, He J: A 5-microRNA signature for lung squamous cell carcinoma diagnosis and hsa-miR-31 for prognosis. Clin Cancer Res. 2011, 17: 6802-6811. 10.1158/1078-0432.CCR-11-0419CrossRefPubMed

29.

Peng Y, Dai Y, Hitchcock C, Yang X, Kassis ES, Liu L, Luo Z, Sun HL, Cui R, Wei H, Kim T, Lee TJ, Jeon YJ, Nuovo GJ, Volinia S, He Q, Yu J, Nana-Sinkam P, Croce CM: Insulin growth factor signaling is regulated by microRNA-486, an underexpressed microRNA in lung cancer. Proc Natl Acad Sci U S A. 2013, 110: 15043-15048. 10.1073/pnas.1307107110PubMedCentralCrossRefPubMed

30.

Li Y, Fan S, Koo J, Yue P, Chen ZG, Owonikoko TK, Ramalingam SS, Khuri FR, Sun SY: Elevated expression of eukaryotic translation initiation factor 4E is associated with proliferation, invasion and acquired resistance to erlotinib in lung cancer. Cancer Biol Ther. 2012, 13: 272-280. 10.4161/cbt.18923PubMedCentralCrossRefPubMed

31.

Batra V, Maris JM, Kang MH, Reynolds CP, Houghton PJ, Alexander D, Kolb EA, Gorlick R, Keir ST, Carol H, Lock R, Billups CA, Smith MA: Initial testing (stage 1) of SGI-1776, a PIM1 kinase inhibitor, by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012, 59: 749-752. 10.1002/pbc.23364PubMedCentralCrossRefPubMed

32.

Kim W, Youn H, Kwon T, Kang J, Kim E, Son B, Yang HJ, Jung Y, Youn B: PIM1 kinase inhibitors induce radiosensitization in non-small cell lung cancer cells. Pharmacol Res. 2013, 70: 90-101. 10.1016/j.phrs.2013.01.005CrossRefPubMed

33.

Patel MR, Jay-Dixon J, Sadiq AA, Jacobson BA, Kratzke RA: Resistance to EGFR-TKI can be mediated through multiple signaling pathways converging upon cap-dependent translation in EGFR-wild type NSCLC. J Thorac Oncol. 2013, 8: 1142-1147. 10.1097/JTO.0b013e31829ce963PubMedCentralCrossRefPubMed

34.

Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q, Qin L, Wu X, Zheng Y, Yang Y, Tian W, Zhang Q, Wang C, Zhang Q, Zhuang SM, Zheng L, Liang A, Tao W, Cao X: Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011, 19: 232-243. 10.1016/j.ccr.2011.01.001CrossRefPubMed

Title: Pim-1 kinase is a target of miR-486-5p and eukaryotic translation initiation factor 4E, and plays a critical role in lung cancer
Authors: Wenshuai Pang
Xin Tian
Fan Bai
Ruiyu Han
Juan Wang
Haitao Shen
Xianghong Zhang
Yueping Liu
Xia Yan
Feng Jiang
Lingxiao Xing
Publication date: 01-12-2014
Publisher: BioMed Central
Published in: Molecular Cancer / Issue 1/2014
Electronic ISSN: 1476-4598
DOI: https://doi.org/10.1186/1476-4598-13-240

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2014

Overexpression of CIP2A is an independent prognostic indicator in nasopharyngeal carcinoma and its depletion suppresses cell proliferation and tumor growth

A hormone-dependent feedback-loop controls androgen receptor levels by limiting MID1, a novel translation enhancer and promoter of oncogenic signaling

The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis

Maternal embryonic leucine zipper kinase enhances gastric cancer progression via the FAK/Paxillin pathway

Higher FOXP3-TSDR demethylation rates in adjacent normal tissues in patients with colon cancer were associated with worse survival

WNK1-OSR1 kinase-mediated phospho-activation of Na+-K+-2Cl- cotransporter facilitates glioma migration

Keynote webinar | Spotlight on antibody–drug conjugates in cancer